Alan D. D’Andrea

This study shows DNA-PK enforces the S/G2 checkpoint in ATM-deficient cells, reducing ATR inhibitor efficacy, and suggests combining ATR and DNA-PK inhibition could enhance treatment in such cancers.

This study identifies a defect in MMEJ repair in SMARCB1-deficient tumors, leading to hyper-dependence on the FA/BRCA pathway, which can be targeted for therapy.

This paper shows that Ewing sarcoma cells have reduced POLθ expression and MMEJ activity due to EWS-FLI1 or EWSR1 disruption, making them sensitive to inhibitors of FA, NHEJ, or HR pathways.

This paper identifies a PIP motif in RAD18 essential for PCNA ubiquitination and shows USP1 inhibition leads to synthetic lethality in BRCA1-deficient cells.

This study shows that AR inhibition does not enhance PARP inhibitor efficacy in HR-proficient prostate cancer and instead impairs response in castration-sensitive cells.

This study identifies the CHAMP1 complex as a regulator of heterochromatin assembly and replication fork stability, showing its role in preventing genomic instability in cancer cells.

This study shows HPV16 E6 oncoprotein increases POLQ levels via UBE3A and RAD23A regulation, enhancing MMEJ to promote viral integration and oncogenesis.

This study identifies the CHAMP1 complex's role in heterochromatin assembly and its enhancement of homology-directed DNA repair in specific genomic regions.

This study shows how DYNLL1 and Shieldin regulate DNA end resection and repair pathway choice through interactions with MRE11 and 53BP1 at DSBs.

The paper shows that REV7-CHAMP1 complex promotes homologous recombination repair by inhibiting NHEJ and TLS repair pathways, and its overexpression in tumors correlates with poor prognosis.